The FY2025 (Dec) proxy of Altimmune names 17 peer companies for pay. Among Altimmune and these peers, CEO pay was the highest of 5 and total shareholder return was the lowest of 5.
1st highest of 5in Altimmune and its pay peers, FY2025 (Dec) by CEO pay:
$1.4M$8.0M
5th highest of 5in Altimmune and its pay peers, FY2025 (Dec) by total shareholder return:
$22$206
Pay peer group, FY2025 (Dec) proxy
| Solid Biosciences | ||
| Savara | ||
| aTYR Pharma | ||
| Arbutus Biopharma | ||
| 89bio, Inc. | Not disclosed | Not disclosed |
| Akero Therapeutics, Inc. | Not disclosed | Not disclosed |
| Amylyx Pharmaceuticals | Not disclosed | Not disclosed |
| Anavex Life Sciences | Not disclosed | Not disclosed |
| Arcturus Therapeutics Holdings | Not disclosed | Not disclosed |
| Astria Therapeutics, Inc. | Not disclosed | Not disclosed |
| Atea Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Gossamer Bio, Inc. | Not disclosed | Not disclosed |
| Inhibrx Biosciences, Inc. | Not disclosed | Not disclosed |
| MBX Biosciences, Inc. | Not disclosed | Not disclosed |
| Rezolute, Inc. | Not disclosed | Not disclosed |
| Terns Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Tyra Biosciences | Not disclosed | Not disclosed |
17 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.